Creative Planning
ZVRA icon

Creative Planning’s Zevra Therapeutics ZVRA Stock Holding History

Creative Planning’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234K Buy
16,348
+4,667
+40% +$51.9K ﹤0.01% 3763
2026
Q1 		$109K Buy
11,681
+137
+1% +$1.24K ﹤0.01% 3888
2025
Q4 		$103K Sell
11,544
-1,529
-12% -$14.5K ﹤0.01% 3711
2025
Q3 		$124K Buy
13,073
+2,620
+25% +$26.3K ﹤0.01% 3636
2025
Q2 		$92.1K Buy
+10,453
New +$84.8K ﹤0.01% 3447
2025
Q1 		– Sell
-370
Closed -$3.09K – 3759
2024
Q4 		$3.09K Buy
+370
New +$3.16K ﹤0.01% 3436
2021
Q2 		– Sell
-16,077
Closed -$148K – 2632
2021
Q1 		$148K Buy
+16,077
New +$140K ﹤0.01% 2169
2020
Q2 		– Sell
-28,132
Closed -$101K – 2156
2020
Q1 		$101K Hold
28,132
– – ﹤0.01% 1531
2019
Q4 		$171K Hold
28,132
– – ﹤0.01% 1669
2019
Q3 		$310K Hold
28,132
– – ﹤0.01% 1345
2019
Q2 		$788K Hold
28,132
– – ﹤0.01% 863
2019
Q1 		$752K Hold
28,132
– – ﹤0.01% 848
2018
Q4 		$801K Hold
28,132
– – ﹤0.01% 760
2018
Q3 		$2.16M Sell
28,132
-106
-0.4% -$8.28K 0.01% 461
2018
Q2 		$2.94M Sell
28,238
-107
-0.4% -$10.4K 0.01% 380
2018
Q1 		$3.58M Hold
28,345
– – 0.01% 325
2017
Q4 		$1.84M Hold
28,345
– – 0.01% 487
2017
Q3 		$1.68M Hold
28,345
– – 0.01% 519
2017
Q2 		$1.81M Sell
28,345
-13
-0% -$856 0.01% 466
2017
Q1 		$2.22M Buy
28,358
+638
+2% +$38.8K 0.01% 389
2016
Q4 		$1.31M Buy
27,720
+2,045
+8% +$126K 0.01% 526
2016
Q3 		$1.84M Buy
25,675
+25,125
+4,568% +$1.79M 0.01% 394
2016
Q2 		$35K Hold
550
– – ﹤0.01% 2398
2016
Q1 		$128K Hold
550
– – ﹤0.01% 1482
2015
Q4 		$175K Buy
+550
New +$149K ﹤0.01% 1285

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Creative Planning's ZVRA Position: Q2 2026 in Review

Creative Planning increased its Zevra Therapeutics (ZVRA) stake by 40% in Q2 2026, buying an estimated $51.9K and bringing the position to 16,348 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #3763.

Creative Planning first reported a position in ZVRA in Q4 2015 and has held it in 25 quarters since. The position peaked at $3.58M in Q1 2018. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Creative Planning held 16,348 shares of Zevra Therapeutics worth $234K as of Q2 2026.
  • Creative Planning bought 4,667 Zevra Therapeutics shares in Q2 2026, an estimated $51.9K.
  • Zevra Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3763 holding.
  • Creative Planning first reported a position in Zevra Therapeutics in Q4 2015 and has held it in 25 quarters since.
  • Creative Planning's Zevra Therapeutics position peaked at $3.58M in Q1 2018.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.